Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1925443 | 0.85 | KMT2A (0.41) | HSD11B1BCAT2BMP1MEN1KMT2A | |
| SCHEMBL1950523 | 0.85 | HSD11B1 (0.36) | HSD11B1BCAT2BMP1ELANEMEN1 | |
| SCHEMBL1950189 | 0.82 | ITGAV (0.40) | HSD11B1BCAT2BMP1CYP2C19KMT2A | |
| SCHEMBL1948969 | 0.82 | ALDH1A1 (0.39) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1952112 | 0.82 | BMP1 (0.38) | HSD11B1BCAT2BMP1SMN1; SMN2ITGAV | |
| SCHEMBL1951634 | 0.81 | MMP1 (0.31) | — | |
| SCHEMBL1926036 | 0.81 | HSD11B1 (0.40) | HSD11B1BCAT2BMP1ELANEMEN1 | |
| SCHEMBL1927510 | 0.81 | BMP1 (0.37) | HSD11B1BCAT2BMP1ELANEITGAV | |
| SCHEMBL1925989 | 0.80 | BMP1 (0.36) | HSD11B1BCAT2BMP1ITGAV | |
| SCHEMBL1948946 | 0.79 | BMP1 (0.38) | BCAT2BMP1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | claimed |
| EP-2509942-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | Johns Hopkins University (US) | 2012-10-17 | — | — | EP | claimed |
| EP-2509941-B1 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | HSD11B1 342/4885BCAT2 1590/4885BMP1 3652/4885 |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | HSD11B1 323/4885BCAT2 564/4885BMP1 3173/4885 |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, NOS2 | HSD11B1 358/4885BCAT2 1680/4885BMP1 3620/4885 |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | HSD11B1 342/4885BCAT2 1590/4885BMP1 3652/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | HSD11B1 342/4885BCAT2 1590/4885BMP1 3652/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | HSD11B1 323/4885BCAT2 564/4885BMP1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.